Immuron Ltd: Immuron CEO presentation to Emerging Growth Conference
Immuron Ltd: Immuron Plans Phase 2 Trial for IMM-529 following FDA review
Immuron Ltd: Appendix 4E and Preliminary Final Report
Immuron Ltd: Immuron CEO presentation to Peak Biotech Showcase
Immuron Ltd: New US DoD Research Award to develop enhanced Travelan
Immuron Ltd: Immuron CEO presentation to MarketOpen Direct Connect
Immuron Ltd: Immuron CEO to host webinar on MarketOpen Direct Connect
Immuron Ltd: Change in substantial holding
Immuron Ltd: Immuron CEO to present at TechKnow Invest Roadshow
Immuron Ltd: Immuron CEO to present at Emerging Growth Conference
Immuron Ltd: Notification of cessation of securities - IMC
Immuron Ltd: Immuron Travelan record sales globally, Australia and USA
Immuron Ltd: Immuron CEO Steven Lydeamore presentation to Sharewise
Immuron Ltd: Immuron CEO Steven Lydeamore to present at Sharewise
Immuron Ltd: Immuron lodges Form F-3 and ATM Prospectus with U.S. SEC
Immuron Ltd: IMM-529 pre-IND FDA filing
Immuron Ltd: Initial Director's Interest Notice JJ
Immuron Ltd: Final Director's Interest Notice RA
Immuron Ltd: Board Changes
Immuron Ltd: Immuron CEO Steven Lydeamore to present at Peak Sky High
No Data
No Data